Belantamab mafodotin is a B-cell maturation antigen (BCMA)-targeting antibody-drug conjugate (ADC) used for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.